Site-Specific Codes for Neoadjuvant Therapy Treatment Effect

Schemas: Lymphoma, Lymphoma CLL/SLL, Mycosis Fungoides, Primary Cutaneous Lymphoma (excluding MF and SS), Plasma Cell Myeloma, Plasma Cell Disorders, HemeRetic, Ill-Defined Other

*Neoadjuvant Therapy--Treatment Effect* data item [NAACCR # 1634] is related to the *Neoadjuvant Therapy* data item [NAACCR # 1632]. This data item records the findings from the post neoadjuvant therapy surgical pathology report ONLY when surgery is performed after neoadjuvant therapy. This set of codes applies to the schemas: Lymphoma, Lymphoma CLL/SLL, Mycosis Fungoides, Primary Cutaneous Lymphoma (excluding MF and SS), Plasma Cell Myeloma, Plasma Cell Disorders, HemeRetic, Ill-Defined Other.

Coding Instructions

1. ALWAYS code to 0, no neoadjuvant therapy (not applicable), for the following schemas
   a. HemeRetic  00830
   b. Ill-Defined Other  99999
   c. Lymphoma (excluding CLL/SLL)  00790
   d. Lymphoma CLL/SLL  00795
   e. Mycosis Fungoides  00811
   f. Plasma Cell Disorders  00822
   g. Plasma Cell Myeloma  00821
   h. Primary Cutaneous Lymphoma (excluding MF and SS)  00812

2. Assign the appropriate code using the set of Site-Specific Codes for Neoadjuvant Therapy--Treatment Effect (Appendix C) that corresponds to the primary site when an organ is the primary site for a lymphoma